Reasons To Invest
RNA is the cell software, and by decoding it, we can recode biology. Genomic Expression is pioneering a next-generation RNA AI platform that not only improves patient outcomes now but fundamentally shifts how we approach cancer treatment and drug discovery and development in the future - potentially bending the cost and time curve for new drug approvals.
The Problem: A Static Standard of Care Treating All Cancer Patients the Same Way
Despite significant advancements in cancer treatment, the reality remains stark: 50-80% of patients do not benefit from standard of care, with drugs that are expensive and costly to develop. When patients recur or do not respond they have access to DNA panels, which fail to provide truly individualized treatments, leaving the majority of patients without viable options.
Our Solution: OneRNA® Platform to Truly Individualize Cancer Treatment
Genomic Expression’s OneRNA® platform offers a groundbreaking alternative. By quantifying all 20,000+ mRNAs in a patient’s sample, OneRNA® can identify and quantify the most effective treatments on an individual basis. Our platform has been tested in five cancer types and clinically validated in breast and ovarian cancers, showing a diagnostic yield of nearly 100% providing solutions for ALL patients.
We are ready to launch commercially now to help breast and ovarian cancer patients navigate their treatment options when they don't respond or recur after standard of care.
Finally, we are advancing methods to rapidly translate RNA code to RNA Therapeutics.
1. We can save lives now
Saving cancer patients' lives NOW repurposing FDA-approved drugs by analyzing patient’s unique RNA profiles. Validated in breast and ovarian cancer with close to 100% diagnostic yield and high concordance with other single biomarker tests. Broad patent has been filed, and regulatory approvals are in place (CLIA) to launch into the $3B women’s cancer market.
2. Commercial Traction
We are commercial stage, and close to positive cash flow. There is a payor code specific for RNA-seq based tests reimbursing us $3,000 per OneRNA® test, and our margins are healthy.
We are in-network with major payors, including Medicare, which covers 50% of all cancer patients.
A potential $3.5M NCI contract is under consideration.
3. Strong Partnerships
We have a long-standing partnership with Rutgers and the US National Cancer Institute and support from major patient organisations. We have discussions with most of the large oncology-focused hospitals in the USA. We automated lead generation processes for deals with pharma companies to design and de-risk clinical studies and develop companion diagnostics OneRNA® algorithms (AI).
